Journal: Oncology Reports

Article Title: Long non-coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR-675

doi: 10.3892/or.2020.7608

Figure Lengend Snippet: H19 expression is negatively related to sorafenib sensitivity in HCC cell linws (Huh7, Hep3B, SNU-449, SNU-387). (A) Cell viability was examined by CCK-8 assay in four HCC cell lines subjected to sorafenib treatment. (B) Statistical analysis of the IC 50 in four HCC cell lines subjected to sorafenib treatment. (C) Relative mRNA levels of H19 as measured by RT-qPCR and normalized to β-actin in four HCC cell lines. (D) Cell proliferation was examined by EdU assay in four HCC cell lines subjected to sorafenib treatment. **P<0.01, ***P<0.001, compared to the control. HCC, hepatocellular carcinoma; IC 50 , half maximal inhibitory concentration.

Article Snippet: Human HCC cell lines (Huh7, Hep3B, SNU-449, SNU-387) were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA).

Techniques: Expressing, CCK-8 Assay, Quantitative RT-PCR, EdU Assay, Control, Concentration Assay

Journal: Oncology Reports

Article Title: Long non-coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR-675

doi: 10.3892/or.2020.7608

Figure Lengend Snippet: H19 knockdown sensitizes HCC cells to sorafenib in vitro . (A) Sorafenib sensitivity of HCC cells transfected with NC siRNA or H19 siRNA. (B) Proliferative capacity of HCC cells transfected with NC siRNA or H19 siRNA and subjected to sorafenib treatment. **P<0.01, ***P<0.001, compared with the sorafenib group. (C) H19 expression in HCC cells transfected with NC siRNA or H19 siRNA and subjected to sorafenib treatment. *P<0.05, **P<0.01, ***P<0.001, compared to the control. HCC, hepatocellular carcinoma; NC, negative control.

Article Snippet: Human HCC cell lines (Huh7, Hep3B, SNU-449, SNU-387) were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA).

Techniques: Knockdown, In Vitro, Transfection, Expressing, Control, Negative Control

Journal: Oncology Reports

Article Title: Long non-coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR-675

doi: 10.3892/or.2020.7608

Figure Lengend Snippet: H19 knockdown inhibits EMT and H19 positively regulates miR-675. (A) Immunofluorescence staining showed that E-cadherin (green) and vimentin (green) levels were altered after transfection of NC siRNA or H19 siRNA in the SNU-449 and SNU-387 cells. (B) E-cadherin and vimentin as assessed by western blot analysis. GAPDH was used as loading control. (C) Relative mRNA levels of miR-675 were measured by RT-qPCR and normalized to U6 after transfection of NC siRNA or H19 siRNA in four HCC cell lines. *P<0.05, **P<0.01, ***P<0.001, compared to the control. HCC, hepatocellular carcinoma; NC, negative control; EMT, epithelial-mesenchymal transition.

Article Snippet: Human HCC cell lines (Huh7, Hep3B, SNU-449, SNU-387) were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA).

Techniques: Knockdown, Immunofluorescence, Staining, Transfection, Western Blot, Control, Quantitative RT-PCR, Negative Control

Journal: Oncology Reports

Article Title: Long non-coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR-675

doi: 10.3892/or.2020.7608

Figure Lengend Snippet: miR-675 regulates sensitivity of HCC cells to sorafenib. (A) Sorafenib sensitivity of HCC cells transfected with NC siRNA, miR-675 mimic, or miR-675 inhibitor. (B) Proliferation of HCC cells transfected with NC siRNA, miR-675 mimic, or miR-675 inhibitor in the presence of sorafenib. ***P<0.001, compared with the sorafenib group. (C) Expression of miR-675 in HCC cells transfected with NC siRNA, miR-675 mimic, or miR-675 inhibitor in the presence of sorafenib. *P<0.05, **P<0.01, ***P<0.001. HCC, hepatocellular carcinoma; NC, negative control.

Article Snippet: Human HCC cell lines (Huh7, Hep3B, SNU-449, SNU-387) were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA).

Techniques: Transfection, Expressing, Negative Control

Journal: Oncology Reports

Article Title: Long non-coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR-675

doi: 10.3892/or.2020.7608

Figure Lengend Snippet: miR-675 alters EMT. (A) Immunofluorescence showed that the staining of E-cadherin (green) and vimentin (green) was altered after transfection with the miR-675 mimic, inhibitor, or NC siRNA in SNU-449 and SNU-387 cells. (B) E-cadherin and vimentin levels in HCC cells transfected with NC siRNA, miR-675 mimic, or miR-675 inhibitor in the presence of sorafenib. HCC, hepatocellular carcinoma; NC, negative control; EMT, epithelial-mesenchymal transition.

Article Snippet: Human HCC cell lines (Huh7, Hep3B, SNU-449, SNU-387) were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA).

Techniques: Immunofluorescence, Staining, Transfection, Negative Control

Journal: Oncology Reports

Article Title: Long non-coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR-675

doi: 10.3892/or.2020.7608

Figure Lengend Snippet: miR-675 mediates the regulatory effect of lncRNA H19 on sorafenib sensitivity. Sorafenib sensitivity of HCC cells transfected with NC siRNA or H19 siRNA was evaluated by CCK-8 assay in the presence of the miR-675 mimic for 48 h. HCC, hepatocellular carcinoma; NC, negative control.

Article Snippet: Human HCC cell lines (Huh7, Hep3B, SNU-449, SNU-387) were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA).

Techniques: Transfection, CCK-8 Assay, Negative Control

Journal: Redox Biology

Article Title: Small molecule screen identifies pyrimethamine as an inhibitor of NRF2-driven esophageal hyperplasia

doi: 10.1016/j.redox.2023.102901

Figure Lengend Snippet: PYR shortened NRF2 half-life and promoted NRF2 ubiquitination in NRF2 Mut ESCC cells. (A) NRF2 half-life was shortened by PYR (10 μM) and MIT (20 nM), but not by MTX (50 nM), in NRF2 Mut -KYSE70 cells. (B) NRF2 half-life was reduced by PYR (10 μM) and MIT (20 nM) in NRF2 Mut -KYSE180 cells. (C) NRF2 half-life was not changed by PYR (10 μM) and MIT (20 nM) in NRF2 WT -KYSE450 cells. (D) PYR (10 μM), but not MIT (20 nM), promoted NRF2 ubiquitination in NRF2 Mut -KYSE70 cells in the presence or absence of MG132 (a proteasomal inhibitor). (E) PYR (10 μM), but not MIT (20 nM), promoted NRF2 ubiquitination in NRF2 Mut -KYSE180 cells in the presence or absence of MG132. (F) PYR (10 μM), but not MIT (20 nM), slightly promoted NRF2 ubiquitination in NRF2 WT -KYSE450 cells only in the presence of MG132. *P < 0.05.

Article Snippet: NQO1-YFP H1299 cells (human lung adenocarcinoma), KYSE70 ( NRF2 W24C ), KYSE180 ( NRF2 D77V ) and KYSE450 ( NRF2 WT ) cells (human ESCC, DSMZ, Braunschweig, Germany) [ ] were cultured in Gibco RPMI1640 GlutaMAX (ThermoFisher, Waltham, MA) supplemented with 10% FBS and 1% antibiotics (penicillin/streptomycin).

Techniques: Ubiquitin Proteomics